# PUBLIC SUMMARY DOCUMENT

**Product:** Dansac Nova 2

**Applicant:** Dansac

**Date of SPAP Meeting:** 28 April 2020

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac sought the deletion of one variant, due to low volume, from the current listing of Dansac Nova 2 (SAS Code 9946L) in subgroup 5(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including three variants, is currently listed at a unit price of $1.564, with a maximum monthly quantity of 90 units.

## Substitute products

The nominated substitute product is a variant in the Dansac Nova 2 (SAS Code 9946L) range. The product, including three variants, is currently listed in subgroup 5(a) of the
SAS Schedule at a unit price of $1.564, with a maximum monthly quantity of 90 units.

**Variants to be deleted**

| **Product Code** | **Description** |
| --- | --- |
| 1203-36 | single carbon filter, opaque with fabric backing, extra small, 200ml, belt loops on pouch, mechanical coupling, 36mm ring,  |

 **Nominated substitute – SAS Code 9946L – Dansac Nova 2**

| **Product Code** | **Description** |
| --- | --- |
| 1203-43 | single carbon filter, opaque with fabric backing, extra small, 200ml, belt loops on pouch, mechanical coupling, 43mm ring, |

## Background

This product was first listed on the SAS Schedule in April 2011.

## Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring a two-piece closed pouch with mechanical coupling.

### Financial Analysis

The deletion of one variant is recommended. Substitute products are currently listed in subgroup 5(a) of the SAS Schedule at the same cost and maximum monthly quantity. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

## Panel Recommendation

The Panel recommended the deletion of one variant from the product range for
Dansac Nova 2 (SAS Code 9946L) listed in subgroup 5(a) of the SAS Schedule at the unit price of $1.564, with a maximum monthly quantity of 90 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the Panel recommended date (28 April 2020) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Dansac agrees with the Panel’s recommendation.